Gut instincts: Explorations in intestinal physiology and drug delivery

International Journal of Pharmaceutics

Volumn 364, Issue 2, 2008, Pages 213-226

  McConnell, Emma L ^a   Fadda, Hala M ^a   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biopharmaceutics; Colonic delivery; Dissolution; Gastrointestinal tract; In vitro in vivo correlation; Inflammatory bowel disease; Large intestine; Modified release; Oral drug delivery; Vaccination

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AMYLOSE; ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; CLIPPER; CREMOPHOR; ETHYL CELLULOSE; EUDRAGIT; FLUOROURACIL; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; INSULIN; MACROGOL; MESALAZINE; METOPROLOL; NIFEDIPINE; NITRAZEPAM; NIZATIDINE; OMEPRAZOLE; OPIATE DERIVATIVE; POLOXAMER; POLYSORBATE 20; PREDNISOLONE 3 SULFOBENZOATE; PROTON PUMP INHIBITOR; RANITIDINE; RECOMBINANT HUMAN INSULIN; SIMVASTATIN; SORBITAN LAURATE; SORIVUDINE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INTESTINE FLORA; INTESTINE FLUID; INTESTINE FUNCTION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 43249121029     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.012     Document Type: Review

References (225)

1. Aburub A., Risley D.S., and Mishra D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int. J. Pharm. 347 (2008) 16-22
2. Adkin D.A., Davis S.S., Sparrow R.A., Huckle P.D., Phillips A.J., and Wilding I.R. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm. Res. 12 (1995) 393-396
3. Adkin D.A., Davis S.S., Sparrow R.A., Huckle P.D., Phillips A.J., and Wilding I.R. The effects of pharmaceutical excipients on small intestinal transit. Br. J. Clin. Pharmacol. 39 (1995) 381-387
4. Adkin D.A., Davis S.S., Sparrow R.A., Huckle P.D., and Wilding I.R. The effect of mannitol on the oral bioavailability of cimetidine. J. Pharm. Sci. 84 (1995) 1405-1409
5. Akerlund J.E., Bjorkhem I., Angelin B., Liljeqvist L., and Einarsson K. Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut 35 (1994) 1116-1120
6. Allan R., Steinberg D.M., Dixon K., and Cooke W.T. Changes in the bidirectional sodium flux across the intestinal mucosa in Crohn's disease. Gut 16 (1975) 201-204
7. Ammon H.V., Loeffler R.E., and Luedtke L.A. Effects of lysophosphatidylcholine on jejunal water and solute transport in the rat in vivo. Lipids 18 (1983) 428-433
8. Annese V., Bassotti G., Napolitano G., Usai P., Andriulli A., and Vantrappen G. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand. J. Gastroenterol. 32 (1997) 1107-1117
9. Arnold R. Diagnosis and differential diagnosis of hypergastrinemia. Wien. Klin. Wochenschr. 119 (2007) 564-569
10. Ashiru, D.A.I., Patel, R., Basit, A.W., in press. Polyethylene Glycol 400 Enhances the Bioavailability of a BCS Class III Drug (Ranitidine) in Male Subjects But Not Females. Pharm. Res. doi:10.1007/s11095-008-9635-y.
11. Aunins J.G., Southard M.Z., Myers R.A., Himmelstein K.J., and Stella V.J. Dissolution of carboxylic acids. III. The effect of polyionizable buffers. J. Pharm. Sci. 74 (1985) 1305-1316
12. Banwell J.G., Gorbach S.L., Pierce N.F., Mitra R., and Mondal A. Acute undifferentiated human diarrhea in the tropics. II. Alterations in intestinal fluid and electrolyte movements. J. Clin. Invest. 50 (1971) 890-900
13. Barbara G., De Giorgio R., Stanghellini V., Cremon C., Salvioli B., and Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 20 Suppl. 2 (2004) 1-9
14. Barone J.A., Jessen L.M., Colaizzi J.L., and Bierman R.H. Cisapride: a gastrointestinal prokinetic drug. Ann. Pharmacother. 28 (1994) 488-500
15. Basit A.W. Advances in colonic drug delivery. Drugs 65 (2005) 1991-2007
16. Basit A.W., and Lacey L.F. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int. J. Pharm. 227 (2001) 157-165
17. Basit A.W., Newton J.M., and Lacey L.F. Susceptibility of the H-2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int. J. Pharm. 237 (2002) 23-33
18. Basit A.W., Newton J.M., Short M.D., Waddington W.A., Ell P.J., and Lacey L.F. The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharm. Res. 18 (2001) 1146-1150
19. Basit A.W., Podczeck F., Michael Newton J., Waddington W.A., Ell P.J., and Lacey L.F. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur. J. Pharm. Sci. 21 (2004) 179-189
20. Basit A.W., Podczeck F., Newton J.M., Waddington W.A., Ell P.J., and Lacey L.F. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm. Res. 19 (2002) 1368-1374
21. Berggren S., Gall C., Wollnitz N., Ekelund M., Karlbom U., Hoogstraate J., Schrenk D., and Lennernas H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4 (2007) 252-257
22. Bergheim I., Bode C., and Parlesak A. Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol. 5 (2005) 34
23. Bergheim I., Bode C., and Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin. Pharmacol. 5 (2005) 4
24. Bernhardt H., and Knoke M. Mycological aspects of gastrointestinal microflora. Scand. J. Gastroenterol. 32 (1997) 102-106
25. Bieche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., Beaune P., and De Waziers I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 17 (2007) 731-742
26. 12C-nifedipine. Eur. J. Clin. Pharmacol. 50 (1996) 195-201
27. Boni J.E., Brickl R.S., and Dressman J. Is bicarbonate buffer suitable as a dissolution medium?. J. Pharm. Pharmacol. 59 (2007) 1375-1382
28. Bozkurt T., Adler G., Koop I., and Arnold R. Effect of atropine on intestinal phase of pancreatic secretion in man. Digestion 41 (1988) 108-115
29. Braganza J.M., Herman K., Hine P., Kay G., and Sandle G.I. Pancreatic enzymes in human duodenal juice-a comparison of responses in secretin pancreozymin and Lundh Borgstrom tests. Gut 19 (1978) 358-366
30. Bratten J., and Jones M.P. Evaluation of duodenal acid exposure in healthy subjects using a radiotelemetry pH monitoring system. Gastroenterol. Clin. North. Am. 130 (2006) A624
31. Bubenik G.A. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol. Signals Recept. 10 (2001) 350-366
32. Buggins T.R., Dickinson P.A., and Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Deliv. Rev. 59 (2007) 1482-1503
33. Buhmann S., Kirchhoff C., Ladurner R., Mussack T., Reiser M.F., and Lienemann A. Assessment of colonic transit time using MRI: a feasibility study. Eur. Radiol. 17 (2007) 669-674
34. Camilleri M. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterol. Motil. 19 (2007) 40-45
35. Camilleri M., Andrews C.N., Bharucha A.E., Carlson P.J., Ferber I., Stephens D., Smyrk T.C., Urrutia R., Aerssens J., Thielemans L., Gohlmann H., Van Den Wyngaert I., and Coulie B. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132 (2007) 17-25
36. Camilleri M., and Ford M.J. Review article: colonic sensorimotor physiology in health, and its alteration in constipation and diarrhoeal disorders. Aliment. Pharmacol. Ther. 12 (1998) 287-302
37. Camilleri M., Thompson W.G., Fleshman J.W., and Pemberton J.H. Clinical management of intractable constipation. Ann. Intern. Med. 121 (1994) 520-528
38. Canaparo R., Nordmark A., Finnstrom N., Lundgren S., Seidegard J., Jeppsson B., Edwards R.J., Boobis A.R., and Rane A. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin. Pharmacol. Toxicol. 100 (2007) 240-248
39. Cani P.D., Delzenne N.M., Amar J., and Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol. Biol. (Paris) (2008)
40. Carrette O., Favier C., Mizon C., Neut C., Cortot A., Colombel J.F., and Mizon J. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig. Dis. Sci. 40 (1995) 2641-2646
41. Catteau D., Barthelemy C., Deveaux M., Robert H., Trublin F., Marchandise X., and Van Drunen H. Contribution of scintigraphy to verify the reliability of different preparation processes for enteric coated capsules. Eur. J. Drug. Metab. Pharmacokinet. 19 (1994) 91-98
42. Ch'ng H.S., Park H., Kelly P., and Robinson J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. II. Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 74 (1985) 399-405
43. Chambers S.J., Wickham M.S., Regoli M., Bertelli E., Gunning P.A., and Nicoletti C. Rapid in vivo transport of proteins from digested allergen across pre-sensitized gut. Biochem. Biophys. Res. Commun. 325 (2004) 1258-1263
44. Chin T.W., Loeb M., and Fong I.W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39 (1995) 1671-1675
45. Colson R.H., Watson B.W., Fairclough P.D., Walker-Smith J.A., Campbell C.A., Bellamy D., and Hinsull S.M. An accurate, long-term, pH-sensitive radio pill for ingestion and implantation. Biotelem. Patient Monit. 8 (1981) 213-227
46. Coupe A.J., Davis S.S., and Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy-subjects. Pharm. Res. 8 (1991) 360-364
47. Cowen D.L., and Helfand W.H. Pharmacy: An Illustrated History (1990), Harry N Abrams Inc., New York
48. Cummings J.H., Banwell J.G., Segal I., Coleman N., Englyst H.N., and Macfarlane G.T. The amount and composition of large bowel contents in man. Gastroenterology (1990) 98
49. 13C]glucose microspheres as a model for drug delivery to the colon. J. Control. Release 40 (1996) 123-131
50. Cummings J.H., Pomare E.W., Branch W.J., Naylor C.P., and Macfarlane G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28 (1987) 1221-1227
51. Dancygier H. Aids and the gastrointestinal tract. Endoscopy 30 (1998) 222-229
52. Davis S.S., Hardy J.G., and Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986) 886-892
53. Dew M.J., Hughes P.J., Lee M.G., Evans B.K., and Rhodes J. An oral preparation to release drugs in the human colon. Br. J. Clin. Pharmacol. 14 (1982) 405-408
54. Digenis G.A., Sandefer E.P., Parr A.F., Beihn R., McClain C., Scheinthal B.M., Ghebre-Sellassie I., Iyer U., Nesbitt R.U., and Randinitis E. Gastrointestinal behavior of orally administered radiolabeled erythromycin pellets in man as determined by gamma scintigraphy. J. Clin. Pharmacol. 30 (1990) 621-631
55. DiMagno E.P., Malagelada J.R., Go V.L., and Moertel C.G. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N. Engl. J. Med. 296 (1977) 1318-1322
56. Dobson C.L., Davis S.S., Chauhan S., Sparrow R.A., and Wilding I.R. The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations. Pharm. Res. 16 (1999) 92-96
57. Dobson C.L., Davis S.S., Chauhan S., Sparrow R.A., and Wilding I.R. The effect of ileal brake activators on the oral bioavailability of atenolol in man. Int. J. Pharm. 248 (2002) 61-70
58. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
59. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., Gill S.R., Nelson K.E., and Relman D.A. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
60. Efentakis M., and Dressman J.B. Gastric juice as a dissolution medium: surface tension and pH. Eur. J. Drug. Metab. Pharmacokinet. 23 (1998) 97-102
61. Elson C.O. Experimental models of intestinal inflammation: new insights into mechanisms of mucosal homeostasis. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., and McGhee J.R. (Eds). Mucosal Immunology (2001), Academic Press, London
62. Englund G., Rorsman F., Ronnblom A., Karlbom U., Lazorova L., Grasjo J., Kindmark A., and Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29 (2006) 269-277
63. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., and Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29 (1988) 1035-1041
64. Ewe K., Schwartz S., Petersen S., and Press A.G. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig. Dis. Sci. 44 (1999) 1434-1439
65. Fadda H., and Basit A.W. Drug solubility in human jejunal fluids and physiologically relevant media: relative importance of buffer composition and intestinal surfacts. AAPS J. 9 (2007) T2033
66. Fadda H.M., and Basit A.W. Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. J. Drug. Del. Sci. Tech. 15 (2005) 273-279
67. Fallingborg J., Christensen L.A., Ingeman-Nielsen M., Jacobsen B.A., Abildgaard K., and Rasmussen H.H. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment. Pharmacol. Ther. 3 (1989) 605-613
68. Fallingborg J., Christensen L.A., Jacobsen B.A., and Rasmussen S.N. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig. Dis. Sci. 38 (1993) 1989-1993
69. Fallingborg J., Pedersen P., and Jacobsen B.A. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig. Dis. Sci. 43 (1998) 702-705
70. FDA, 2008. http://www.fda.gov/cber/gdlns/pharmdtasub.pdf, last accessed January 2008.
71. Flach C.F., Qadri F., Bhuiyan T.R., Alam N.H., Jennische E., Holmgren J., and Lonnroth I. Differential expression of intestinal membrane transporters in cholera patients. FEBS Lett. 581 (2007) 3183-3188
72. Florence A.T. Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov Today: Technol. 2 (2005) 75-81
73. Ford D., Howard A., and Hirst B.H. Expression of the peptide transporter hPepT1 in human colon: a potential route for colonic protein nitrogen and drug absorption. Histochem. Cell Biol. 119 (2003) 37-43
74. Galmiche J.P., Coron E., and Sacher-Huvelin S. Capsule endoscopy: recent developments. Gut (2008)
75. Ginski M.J., Taneja R., and Polli J.E. Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system. AAPS PharmSci 1 (1999) E3
76. Gionchetti P., Rizzello F., Morselli C., Tambasco R., and Campieri M. Antiobiotics and probiotics. In: Tözün N., Mantzaris G., Daǧli A., and Schölmerich J. (Eds). Falk Symposium 159. IBD 2007-Achievements in Research and Clinical Practice (2007), AA Dordrecht, The Netherlands, Springer
77. Godbillon J., Evard D., Vidon N., Duval M., Schoeller J.P., Bernier J.J., and Hirtz J. Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon. Br. J. Clin. Pharmacol. 19 Suppl. 2 (1985) 113S-118S
78. Goo R.H., Moore J.G., Greenberg E., and Alazraki N.P. Circadian variation in gastric emptying of meals in humans. Gastroenterology 93 (1987) 515-518
79. 2O) in gastrointestinal contents and the proportion of total body water (T.B.W) in the gastrointestinal tract. J. Clin. Invest. 36 (1957) 289-296
80. Greig E., and Sandle G.I. Diarrhea in ulcerative colitis. The role of altered colonic sodium transport. Ann. N. Y. Acad. Sci. 915 (2000) 327-332
81. Griffin B.T., and O'Driscoll C.M. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J. Pharm. Pharmacol. 58 (2006) 917-925
82. Harris D., Fell J.T., Sharma H.L., and Taylor D.C. GI transit of potential bioadhesive formulations in man-a scintigraphic study. J. Control. Release 12 (1990) 45-53
83. Hasler W.L., Coleski R., Sarosiek I., Mccallum R., Kuo B., Parkman H.P., Sitrin M.D., Lackner J.M., Katz L., Koch K., Wo J.M., Chey W.D., Hutson A., and Semler J. Colon transit and regional colon motor activity in diabetics with gastroparesis compared to healthy volunteers and diabetics with near normal gastric emptying. Gastroenterology 132 (2007) A459-A460
84. Hebden J.M., Blackshaw P.E., Perkins A.C., Wilson C.G., and Spiller R.C. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 14 (2000) 155-161
85. Hinderling P.H., Karara A.H., Tao B., Pawula M., Wilding I., and Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J. Clin. Pharmacol. 47 (2007) 19-25
86. Holtmann G., Kelly D.G., and Dimagno E.P. Nutrients and cyclical interdigestive pancreatic enzyme secretion in humans. Gut 38 (1996) 920-924
87. Ibekwe V.C., Fadda H., McConnell E.L., Khela M.K., Evans D.F., and Basit A.W. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm. Res. 25 (2008) 1828-1835
88. Ibekwe V.C., Fadda H.M., Parsons G.E., and Basit A.W. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int. J. Pharm. 308 (2006) 52-60
89. Ibekwe V.C., Liu F., Fadda H.M., Khela M.K., Evans D.F., Parsons G.E., and Basit A.W. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J. Pharm. Sci. 95 (2006) 2760-2766
90. Intromedic, 2008. www.intromedic.com, last accessed April 2008.
91. Jantratid E., Janssen N., Reppas C., and Dressman J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25 (2008) 1663-1676
92. John V.A., Shotton P.A., Moppert J., and Theobald W. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report. Br. J. Clin. Pharmacol. 19 Suppl. 2 (1985) 203S-206S
93. Johnson B.M., Charman W.N., and Porter C.J.H. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E-d-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 4 (2002) 40
94. Kachel G., Ruppin H., Hagel J., Barina W., Meinhardt M., and Domschke W. Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 90 (1986) 85-93
95. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23 (2006) 165-176
96. Kalantzi L., Persson E., Polentarutti B., Abrahamsson B., Goumas K., Dressman J.B., and Reppas C. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm. Res. 23 (2006) 1373-1381
97. Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T., Lyne A., Stephenson D., Palmen M., and Joseph R.E. Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. Gastroenterology 132 (2007) 66-75
98. Kaus L.C., Fell J.T., Sharma H., and Taylor D.C. On the intestinal transit of a single non-disintegrating object. Int. J. Pharm. 20 (1984) 315-323
99. Keller J., and Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 54 Suppl. 6 (2005) vi1-28
100. Keller J., Runzi M., Goebell H., and Layer P. Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a meal. Am. J. Physiol. 272 (1997) G632-G637
101. Kellow J.E., Borody T.J., Phillips S.F., Tucker R.L., and Haddad A.C. Human interdigestive motility: variations in patterns from esophagus to colon. Gastroenterology 91 (1986) 386-395
102. Kerlin P., and Phillips S. Variability of motility of the ileum and jejunum in healthy humans. Gastroenterology 82 (1982) 694-700
103. Kerlin P., Zinsmeister A., and Phillips S. Relationship of motility to flow of contents in the human small intestine. Gastroenterology 82 (1982) 701-706
104. Khosla R., and Davis S.S. The effect of polycarbophil on the gastric emptying of pellets. J. Pharm. Pharmacol. 39 (1987) 47-49
105. Koch K.M., Parr A.F., Tomlinson J.J., Sandefer E.P., Digenis G.A., Donn K.H., and Powell J.R. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10 (1993) 1027-1030
106. Kurella R.R., Ancha H.B., Ancha H.R., Lightfoot S.A., Guild R.T., and Harty R.F. Obscure GI bleeding due to gastrointestinal stromal tumor (GIST) diagnosed by capsule endoscopy. J. Okla State Med. Assoc. 100 (2007) 415-416
107. Kutteh W.H. Mucosal immunity in the human female reproductive tract. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., and Mcghee J.R. (Eds). Mucosal Immunology (2001), Academic Press, London
108. Kutteh W.H., Mestecky J., and Blackwell R.E. Mucosal immunity of the female genital-tract. Am. J. Reprod. Immunol. Microbiol. 16 (1988) 92-192
109. Lake-Bakaar G., Tom W., Lake-Bakaar D., Gupta N., Beidas S., Elsakr M., and Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 109 (1988) 471-473
110. Lamprecht A., Yamamoto H., Takeuchi H., and Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315 (2005) 196-202
111. Lasser R.B., Bond J.H., and Levitt M.D. The role of intestinal gas in functional abdominal pain. N. Engl. J. Med. 293 (1975) 524-526
112. Lehr C.M., Poelma F.G.J., Junginger H.E., and Tukker J.J. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int. J. Pharm. 70 (1991) 235-240
113. Lennernas H., and Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57 (2005) 273-285
114. Lentz K.A., Hayashi J., Lucisano L.J., and Polli J.E. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int. J. Pharm. 200 (2000) 41-51
115. Levitt M.D., Furne J.K., Strocchi A., Anderson B.W., and Levitt D.G. Physiological measurements of luminal stirring in the dog and human small bowel. J. Clin. Invest. 86 (1990) 1540-1547
116. Ley R.E., Turnbaugh P.J., Klein S., and Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006) 1022-1023
117. Lindahl A., Ungell A.L., Knutson L., and Lennernas H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14 (1997) 497-502
118. Lindenbaum J., Rund D.G., Butler Jr. V.P., Tse-Eng D., and Saha J.R. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N. Engl. J. Med. 305 (1981) 789-794
119. Linskens R.K., Huijsdens X.W., Savelkoul P.H., Vandenbroucke-Grauls C.M., and Meuwissen S.G. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand. J. Gastroenterol. Suppl. (2001) 29-40
120. Longer M.A., Ch'ng H.S., and Robinson J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. III. Oral delivery of chlorothiazide using a bioadhesive polymer. J. Pharm. Sci. 74 (1985) 406-411
121. MacFarlane G.T., and Englyst H.N. Starch utilization by the human large intestinal microflora. J. Appl. Bacteriol. 60 (1986) 195-201
122. MacFarlane G.T., Macfarlane S., and Gibson G.R. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb. Ecol. 35 (1998) 180-187
123. Mandalari G., Faulks R.M., Rich G.T., Lo Turco V., Picout D.R., Lo Curto R.B., Bisignano G., Dugo P., Dugo G., Waldron K.W., Ellis P.R., and Wickham M.S. Release of protein, lipid, and vitamin E from almond seeds during digestion. J. Agric. Food Chem. (2008)
124. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., Befrits R., Midhagen G., Rademaker J., and Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 (2005) 960-965
125. Martinez M., Amidon G., Clarke L., Jones W.W., Mitra A., and Riviere J. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv. Drug Deliv. Rev. 54 (2002) 825-850
126. McConnell E.L., Basit A.W., and Murdan S. Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine 26 (2008) 639-646
127. McConnell E.L., Murdan S., and Basit A.W. An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J. Pharm. Sci. 97 (2008) 3820-3829
128. McConnell E.L., Short M.D., and Basit A.W. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J. Control. Release. 130 (2008) 154-160
129. McConnell E.L., Tutas J., Mohamed M.A.M., Banning D., and Basit A.W. Colonic drug delivery using amylose films: the role of aqueous ethylcellulose dispersions in controlling drug release. Cellulose 14 (2007) 25-34
130. McKinnon R.A., Burgess W.M., Hall P.M., Roberts-Thomson S.J., Gonzalez F.J., and McManus M.E. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36 (1995) 259-267
131. McNamara D.P., Whitney K.M., and Goss S.L. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm. Res. 20 (2003) 1641-1646
132. McNeil N.I., Bingham S., Cole T.J., Grant A.M., and Cummings J.H. Diet and health of people with an ileostomy. 2. Ileostomy function and nutritional state. Br. J. Nutr. 47 (1982) 407-415
133. Mearin, F., Perello, A., Perona, M., Balboa, A., Pages, M., Hernandez, D., Castells, A., 2006. What is the correlation between the bloating sensation and the amount-distribution of intestinal gas in patients with functional abdominal bloating? Digestive Disease Week. Abstract, T1275.
134. Meier Y., Eloranta J.J., Darimont J., Ismair M.G., Hiller C., Fried M., Kullak-Ublick G.A., and Vavricka S.R. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos. 35 (2007) 590-594
135. Merino G., Van Herwaarden A.E., Wagenaar E., Jonker J.W., and Schinkel A.H. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol. 67 (2005) 1765-1771
136. Metcalf A.M., Phillips S.F., Zinsmeister A.R., MacCarty R.L., Beart R.W., and Wolff B.G. Simplified assessment of segmental colonic transit. Gastroenterology 92 (1987) 40-47
137. Mills D.J., Tuohy K.M., Booth J., Buck M., Crabbe M.J., Gibson G.R., and Ames J.M. Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and non-ulcerative colitis subjects. J. Appl. Microbiol. (2008)
138. Milojevic S., Newton J.M., Cummings J.H., Gibson G.R., Botham R.L., Ring S.G., Stockham M., and Allwood M.C. Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J. Control. Release 38 (1996) 75-84
139. Minekus, M., Havenaar, R., 1996. In vitro model of an in vivo digestive tract. US Patent 5525305. Issued 1996.
140. Mooney K.G., Mintun M.A., Himmelstein K.J., and Stella V.J. Dissolution kinetics of carboxylic acids. II. Effect of buffers. J. Pharm. Sci. 70 (1981) 22-32
141. Moreno F.J., Mellon F.A., Wickham M.S., Bottrill A.R., and Mills E.N. Stability of the major allergen Brazil nut 2S albumin (Ber e 1) to physiologically relevant in vitro gastrointestinal digestion. FEBS J. 272 (2005) 341-352
142. Munkholm P., Langholz E., Davidsen M., and Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105 (1993) 1716-1723
143. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., and Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16 (1999) 1876-1882
144. Northfield T.C., and McColl I. Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut 14 (1973) 513-518
145. Nugent S.G., Kumar D., Rampton D.S., Yazaki E., and Evans D.F. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent mesalazine-containing capsules. Gut 46 (2000) A9
146. Nugent S.G., Kumar D., Rampton D.S., Yazaki E., and Evans D.F. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (2001) 571-577
147. O'Driscoll C. Intestinal lymphatic targeting of drugs. STP Pharma Sci. 13 (2003) 17-25
148. Okuda H., Ogura K., Kato A., Takubo H., and Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Therap. 287 (1998) 791-799
149. Olsson C., and Holmgren S. The control of gut motility. Comp. Biochem. Physiol. A-Mol. Integr. Physiol. 128 (2001) 481-503
150. Ozturk S.S., Palsson B.O., and Dressman J.B. Dissolution of ionizable drugs in buffered and unbuffered solutions. Pharm. Res. 5 (1988) 272-282
151. Parr A.F., Sandefer E.P., Wissel P., Mccartney M., McClain C., Ryo U.Y., and Digenis G.A. Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog. Pharm. Res. 16 (1999) 266-271
152. Pedersen B.L., Mullertz A., Brondsted H., and Kristensen H.G. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm. Res. 17 (2000) 891-894
153. Perez de la Cruz Moreno M., Oth M., Deferme S., Lammert F., Tack J., Dressman J., and Augustijns P. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J. Pharm. Pharmacol. 58 (2006) 1079-1089
154. Persson E.M., Gustafsson A.S., Carlsson A.S., Nilsson R.G., Knutson L., Forsell P., Hanisch G., Lennernas H., and Abrahamsson B. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm. Res. 22 (2005) 2141-2151
155. Petri N., Borga O., Nyberg L., Hedeland M., Bondesson U., and Lennernas H. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 44 (2006) 71-79
156. Phillips S.F., and Giller J. The contribution of the colon to electrolyte and water conservation in man. J. Lab. Clin. Med. 81 (1973) 733-746
157. Phillips S.F., and Summerskill W.H. Occlusion of the jejunum for intestinal perfusion in man. Mayo Clin. Proc. 41 (1966) 224-231
158. Phillips S.F., and Summerskill W.H. Water and electrolyte transport during maintenance of isotonicity in human jejunum and ileum. J. Lab. Clin. Med. 70 (1967) 686-698
159. Press A.G., Hauptmann I.A., Hauptmann L., Fuchs B., Fuchs M., Ewe K., and Ramadori G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 12 (1998) 673-678
160. Quan, J.-S., Jiang, H.-L., Kim, E.-M., Jeong, H.-J., Choi, Y.-J., Guo, D.-D., Yoo, M.-K., Lee, H.-G., Cho, C.-S., 2008. pH-sensitive and mucoadhesive thiolated Eudragit-coated chitosan microspheres. Int. J. Pharm. doi:10.1016/j.ijpharm.2008.04.003.
161. Raimundo, A.H., Evans, D.F., Rogers, J., Silk, D.B.A., 1992. Gastrointestinal pH profiles in ulcerative colitis. Gut, Abstract A681.
162. Ramtoola Z., and Corrigan O.I. Influence of the buffering capacity of the medium on the dissolution of drug-excipient mixtures. Drug. Dev. Ind. Pharm. 15 (1989) 2359-2374
163. Rao S.S., Sadeghi P., Beaty J., Kavlock R., and Ackerson K. Ambulatory 24-h colonic manometry in healthy humans. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001) G629-639
164. Rao K.A., Yazaki E., Evans D.F., and Carbon R. Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms. Br. J. Sports Med. 38 (2004) 482-487
165. Rao S.S.C., Read N.W., and Holdsworth C.D. Is the diarrhea in ulcerative-colitis related to impaired colonic salvage of carbohydrate. Gut 28 (1987) 1090-1094
166. Reddymasu S., Sarosick I., Koch K., Hasler W.L., Lackner J., Katz L., Sitrin M.D., Parkman H.P., Wo J.M., Chey W.D., Semler J., Hwang J., Kuo B., and McCallum R. Non-digestible capsule technology to measure frequency of gastric contractions-comparison between healthy and gastroparetic subjects. Gastroenterology 132 (2007) A677-A1677
167. + exchangers NHE2 and NHE3 alter net bicarbonate movement. Am. J. Physiol.-Gastrointest. Liver Physiol. 281 (2001) G159-G163
168. Reynolds J.C. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol. Clin. N. Am. 18 (1989) 437-457
169. Rhodes J., Barnardo D.E., Phillips S.F., Rovelstad R.A., and Hofmann A.F. Increased reflux of bile into the stomach in patients with gastric ulcer. Gastroenterology 57 (1969) 241-252
170. Rich G.T., Bailey A.L., Faulks R.M., Parker M.L., Wickham M.S., and Fillery-Travis A. Solubilization of carotenoids from carrot juice and spinach in lipid phases. I. Modeling the gastric lumen. Lipids 38 (2003) 933-945
171. Rieux A.D., Ragnarsson E.G.E., Gullberg E., Préat V., Schneider Y.-J., and Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25 (2005) 455-465
172. Rizzello F., Gionchetti P., D'arienzo A., Manguso F., Di Matteo G., Annese V., Valpiani D., Casetti T., Adamo S., Prada A., Castiglione G.N., Varoli G., and Campieri M. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 16 (2002) 1109-1116
173. Rubinstein A., and Tirosh B. Mucus gel thickness and turnover in the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion. Pharm. Res. 11 (1994) 794-799
174. Rubinstein A., Tirosh B., Baluom M., Nassar T., David A., Radai R., Glikokabir I., and Friedman M. The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. J. Control. Release 46 (1997) 59-73
175. Rumney C.J., and Rowland I.R. In vivo and in vitro models of the human colonic flora. Crit. Rev. Food Sci. Nutr. 31 (1992) 299-331
176. Sadik R., Abrahamsson H., and Stotzer P.O. Gender differences in gut transit shown with a newly developed radiological procedure. Scand. J. Gastroenterol. 38 (2003) 36-42
177. Safdi A.V. Determination of mesalazine in whole or partial mesalamine delayed-release tablets recovered from fecal samples of healthy volunteers. Am. J. Gastroenterol. (2005) S159
178. Sakkinen M., Marvola J., Kanerva H., Lindevall K., Ahonen A., and Marvola M. Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on gamma scintigraphy. Int. J. Pharm. 307 (2006) 285-291
179. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008) 577-594
180. Sasaki Y., Hada R., Nakajima H., Fukuda S., and Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am. J. Gastroenterol. 92 (1997) 114-118
181. Sathyan G., Hwang S., and Gupta S.K. Effect of dosing time on the total intestinal transit time of non-disintegrating systems. Int. J. Pharm. 204 (2000) 47-51
182. Scheline R.R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 25 (1973) 451-523
183. Schiller C., Frohlich C.P., Geissman T., Siegmund W., Monnikes H., Hosten N., and Weitschies W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22 (2005) 971-979
184. Schuetz E.G., Furuya K.N., and Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275 (1995) 1011-1018
185. Schulze J.D., Ashiru D.A., Khela M.K., Evans D.F., Patel R., Parsons G.E., Coffin M.D., and Basit A.W. Impact of formulation excipients on human intestinal transit. J. Pharm. Pharmacol. 58 (2006) 821-825
186. Schulze J.D., Waddington W.A., Eli P.J., Parsons G.E., Coffin M.D., and Basit A.W. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm. Res. 20 (2003) 1984-1988
187. Schulze J.D.R., Peters E.E., Vickers A.W., Staton J.S., Coffin M.D., Parsons G.E., and Basit A.W. Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int. J. Pharm. 300 (2005) 67-75
188. Schulzke J.D., Bentzel C.J., Schulzke I., Riecken E.O., and Fromm M. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr. Res. 43 (1998) 435-441
189. Seidler U., Lenzen H., Cinar A., Tessema T., Bleich A., and Riederer B. Molecular mechanisms of disturbed electrolyte transport in intestinal inflammation. Ann. N. Y. Acad. Sci. 1072 (2006) 262-275
190. Selen, A., 1991. Factors influencing bioavailablity and bioequivalence. In: Welling, P.G., Tse, F.L.S., Shrikant, V.D. 1991 (Eds.) Pharmaceutical Bioequivalence. Marcel Dekker, New York.
191. Shiner M., Eran M., Freier S., Faber J., and Branski D. Are intraepithelial lymphocytes in celiac mucosa responsible for inducing programmed cell death (apoptosis) in enterocytes? Histochemical demonstration of perforins in cytoplasmic granules of intraepithelial lymphocytes. J. Pediatr. Gastroenterol. Nutr. 27 (1998) 393-396
192. Simon G.L., and Gorbach S.L. Intestinal flora in health and disease. Gastroenterology 86 (1984) 174-193
193. Sinha A., Ball B.J., Connor A.L., Nightingale J., and Wilding I.R. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract. Gastroenterol. 27 (2003) 56-69
194. Smolensky M.H., and Haus E. Circadian rhythms and clinical medicine with applications to hypertension. Am. J. Hypertens. 14 (2001) 280S-290S
195. Sousa T., Paterson R., Moore V., Carlsson A., Abrahamsson B., and Basit A.W. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. (2008) in press
196. Spiller R.C., Trotman I.F., Adrian T.E., Bloom S.R., Misiewicz J.J., and Silk D.B. Further characterisation of the 'ileal brake' reflex in man-effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 29 (1988) 1042-1051
197. Spiller R.C., Trotman I.F., Higgins B.E., Ghatei M.A., Grimble G.K., Lee Y.C., Bloom S.R., Misiewicz J.J., and Silk D.B. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Gut 25 (1984) 365-374
198. Staib A.H., Loew D., Harder S., Graul E.H., and Pfab R. Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device. Eur. J. Clin. Pharmacol. 30 (1986) 691-697
199. Stirrup V., Ledingham S.J., Thomas M., Pye G., and Evans D.F. Redox potential measurement in the gastrointestinal-tract in man. Gut 31 (1990) A1171
200. Strugala V., Allen A., Dettmar P.W., and Pearson J.P. Colonic mucin: methods of measuring mucus thickness. Proc. Nutr. Soc. 62 (2003) 237-243
201. Takeno S., and Sakai T. The role of gut flora metabolism in nitrazepam-induced teratogenicity in rats. Eur. J. Pharmacol. 183 (1990) 2439-2440
202. Thompson, R.P.H., Bloor, J.R., Ede, R.J., Hawkey, C., Hawthorne, B., Muller, F.A., Palmer, R.M.J., 2001. Preserved endogenous cortisol levels during treatment of ulcerative colitis with COLAL-PRED, a novel oral system consistently delivery prednisolone metasulphobenzoate to the colon [abstract]. Gastroenterology 122 (S1), T1207.
203. Thomson A.B.R., Keelan M., Thiesen A., Clandinin M.T., Ropeleski M., and Wild G.E. Small bowel review-diseases of the small intestine. Dig. Dis. Sci. 46 (2001) 2555-2566
204. Thomson M., Fritscher-Ravens A., Mylonaki M., Swain P., Eltumi M., Heuschkel R., Murch S., McAlindon M., and Furman M. Wireless capsule endoscopy in children: a study to assess diagnostic yield in small bowel disease in paediatric patients. J. Pediatr. Gastroenterol. Nutr. 44 (2007) 192-197
205. Tubic-Grozdanis M., Hilfinger J., Amidon G., Kim J., Kijek P., Staubach P., and Langguth P. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. (2008) Online
206. Tuleu C., Basit A.W., Waddington W.A., Ell P.J., and Newton J.M. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules. Aliment. Pharmacol. Ther. 16 (2002) 1771-1779
207. Varum F.J.O., McConnell E.L., Sousa J.J.S., Veiga F., and Basit A.W. Mucoadhesion and the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Sys. 25 (2008) 207-258
208. Vassallo M., Camilleri M., Phillips S.F., Brown M.L., Chapman N.J., and Thomforde G.M. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 102 (1992) 102-108
209. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., Matteuzzi D., and Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13 (1999) 1103-1108
210. Vertzoni M., Dressman J., Butler J., Hempenstall J., and Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 60 (2005) 413-417
211. Wakerly Z., Fell J.T., Attwood D., and Parkins D. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm. Res. 13 (1996) 1210-1212
212. Wallaert B., Colombel J.F., Adenis A., Marchandise X., Hallgren R., Janin A., and Tonnel A.B. Increased intestinal permeability in active pulmonary sarcoidosis. Am. Rev. Resp. Dis. 145 (1992) 1440-1445
213. Watanabe K., Yamashita S., Furuno K., Kawasaki H., and Gomita Y. Metabolism of omeprazole by gut flora in rats. J. Pharm. Sci. 84 (1995) 516-517
214. Weitschies W., Kosch O., Monnikes H., and Trahms L. Magnetic marker monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv. Drug Deliv. Rev. 57 (2005) 1210-1222
215. Whitehead K., Karr N., and Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. (2007)
216. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 17 (2000) 557-620
217. Wilding I. The Enterion capsule: a novel technology for understanding the biopharmaceutical complexity of new molecular entities (NMEs). Drug Del. Tech. (2001) 1
218. Wilson C.G., Washington N., Greaves J.L., Kamali F., Rees J.A., Sempik A.K., and Lampard J.F. Bimodal release of ibuprofen in a sustained-release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int. J. Pharm. 50 (1989) 155-161
219. Wong D., Larrabee S., Clifford K., Tremblay J., and Friend D.R. USP Dissolution Apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J. Control. Release 47 (1997) 173-179
220. Wrong O., Metcalfe A.M., and Gibson A. The electrolyte content faeces. Proc. R. Soc. Med. 58 (1965) 1007-1009
221. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., and Sugiyama Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. J. Control. Release 124 (2007) 1-5
222. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., and Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab. Dispos. 35 (2007) 1142-1148
223. Yang L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J. Control. Release 125 (2008) 77-86
224. Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K., Schuetz J.D., and Schuetz E.G. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13 (2003) 19-28
225. Zhang W.Q., Yan G.Z., Ye D.D., and Chen C.W. Simultaneous assessment of the intraluminal pressure and transit time of the colon using a telemetry technique. Physiol. Meas. 28 (2007) 141-148